Recce Pharmaceutical's Phase II trial of topical gel for skin infections showed positive results, meeting primary efficacy endpoint with no adverse events. The company plans to proceed with Phase III trials focusing on diabetic foot infections, aiming to address antimicrobial resistance.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay